摘要
目的：观察替吉奥胶囊联合多西他赛治疗蒽环类药物耐药的复发转移性乳腺癌的疗效及安全性。方法：31例女性复发转移性乳腺癌患者均给予多西他赛75mg／m2，d1。从给予多西他赛治疗前一天开始，给予口服地塞米松8mg，bid，连用3～5d；替吉奥胶囊80mg／m2，早、晚饭后各服1次，d1～d14。3周为1个周期，2个周期后评价疗效及毒性反应，随访12个月。结果：所有患者接受至少2个周期的治疗后总有效率为48．4％，临床获益率为65．5％；主要毒性反应为血液学毒性和消化道反应，且所有患者均未见明显心、肾毒性。随访12个月，24例存活，生存率为77．4％。结论：替吉奥胶囊联合多西他赛治疗蒽环类药物耐药的复发转移性乳腺癌疗效显著，且安全性较好。
OBJECTIVE： To observe clinical efficacy and safety of Tiji＇ ao capsule combined with doctaxel in the treatment of recurrent metastatic breast cancer （MBC） resistant to anthracycline. METHODS： 31 female patients with recurrent MBC were selected and treated with docetaxel 75 mg/m2, d1. They also received routine treatment since the beginning： dexamethasone 8 mg, bid, po, for consecutive 3-5 day and Tiji＇ ao capsule 80 mg/m2, once after breakfast and supper, d1-d14. A treatment course lasted for 3 weeks. Therapeutic efficacy and toxic reaction were evaluated after 2 weeks, and 12 months follow-up were performed. RESULTS： Total effective rate was 48.4% and clinical benefit rate was 65.5% after all patients received 2 treatment courses at least. Main tox- ic reactions were hematologic toxicity and gastrointestinal response. No obvious heart and kidney toxicity was found. After 12 months follow-up, there were 24 survival cases with survival rate of 77.4%. CONCLUSIONS： Combination of Tiji＇ao capsule com- bined with docetaxel in the treatment of MBC resistant to anthracycline could achieve superior response and sound safety.
出处
《中国药房》
CAS
CSCD
2013年第48期4571-4573,共3页
China Pharmacy
关键词
替吉奥胶囊
多西他赛
蒽环类药物
复发转移性乳腺癌
Tiji＇ ao capsule
Docetaxel
Anthracycline drugs
Recurrent metastatic breast cancer
